WHO ICTRP trial
Propranolol as treatment of patients with angiosarcoma before their standard…
EUCTR2019-002947-41-NL · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2019-002947-41-NL |
|---|---|
| Public title | Propranolol as treatment of patients with angiosarcoma before their standard therapy. |
| Scientific title | Neoadjuvant trial on the efficacy of propranolol monotherapy in angiosarcoma (PROPANGIO). - propranolol in angiosarcoma |
| Primary sponsor | Netherlands Cancer Institute- Antoni van Leeuwenhoek |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Netherlands |
| Conditions | Angiosarcoma;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: propranolol Product Name: propranolol Pharmaceutical Form: Tablet |
| Registration date | Aug 10, 2019 |
| Target size | 14 |
| Secondary IDs | N19PCA |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: